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ABSTRACT
Purpose A computational fluid dynamics (CFD) study examined
the impact of particle size on dissolution rate and residence of
intravitreal suspension depots of Triamcinolone Acetonide (TAC).
Methods A model for the rabbit eye was constructed using
insights from high-resolution NMR imaging studies (Sawada
2002). The current model was compared to other published
simulations in its ability to predict clearance of various intra-
vitreally injected materials. Suspension depots were constructed
explicitly rendering individual particles in various configurations: 4
or 16 mg drug confined to a 100 μL spherical depot, or 4 mg
exploded to fill the entire vitreous. Particle size was reduced
systematically in each configuration. The convective diffusion/
dissolution process was simulated using a multiphase model.
Results Release rate became independent of particle diameter
below a certain value. The size-independent limits occurred for
particle diameters ranging from 77 to 428 μM depending upon
the depot configuration. Residence time predicted for the
spherical depots in the size-independent limit was comparable
to that observed in vivo.
Conclusions Since the size-independent limit was several-fold
greater than the particle size of commercially available
pharmaceutical TAC suspensions, differences in particle size
amongst such products are predicted to be immaterial to their
duration or performance.
KEY WORDS computationalfluiddynamics(CFD).
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ABBREVIATIONS
C drug concentration
Ca mean aqueous humor concentration
Cv mean vitreous concentration
D drug diffusivity (region dependent)
E, F constants used in reference solution for single particle
dissolution
f aqueous humor production rate.
Kh/η hydraulic conductivity (region dependent) divided by
regional viscosity
kv vitreous clearance rate
R radius of single drug particle for reference solution
R0 initial radius of single drug particle for reference solution
Rv radius of spherical vitreous region for reference solution
t time
TAC triamcinolone acetonide
ρ drug density
INTRODUCTION
TRIESENCE™ is a preservative-free suspension of
40 mg/mL Triamcinolone Acetonide (TAC) approved in
the US for visualization during vitrectomy and for treatment
of sympathetic ophthalmia, temporal arteritis, uveitis, and
ocular inflammatory conditions unresponsive to topical
corticosteroids. In the development of this product,a question
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bioavailability. The mean particle diameter measured for
TRIESENCE
™ was 5–6 μm. This was approximately one-
third the particle size measured for KENALOG®-40, a
suspension of TAC preserved with benzyl alcohol. Although
KENALOG®-40 was approved only for intramuscular and
intraarticular use, it had been used off label to treat various
ophthalmic conditions.
Assuming particles are spherically shaped, a three-fold
decrease in particle diameter would require a 27-fold
increase in the number of particles to maintain the same
drug dose. The smaller particles would each have a
surface area that is one-ninth that of the original particles,
and there would be a three-fold increase in total particle
surface area. The dissolution rate could be impacted by
total particle surface area, and in fact, differences were
observed in the in vitro dissolution rates measured for the
two products. The method used was based upon USP Type
II, which subjects the suspension particles to high rates of
shear (stirring). But the hydrodynamic conditions to which
suspension particles are exposed in the eye are vastly
different. Before age 20, the vitreous is a quiescent gel. The
central vitreous liquefies gradually upon aging (2). But even
in the case in which a significant fraction of the vitreous has
become liquefied, the rate of shear produced by eye
movements is probably significantly lower than that of the
USP dissolution test.
Thus, a series of simulations was conducted to determine
the potential influence of particle size on dissolution rate of
TAC suspension depots of varying designs placed in the
vitreous of the rabbit eye. The geometric model was similar
to other geometries used for in silico modeling of ocular
drug disposition (3,4), but was refined using insights
afforded by high resolution NMR imaging (1). It will be
demonstrated that the new geometric model provides
superior predictions for the rate of clearance of various
substances injected into the vitreous. This was accomplished
by developing a computational model that is able to predict
dissolution from the surface of individual particles. The
validity of this method will be demonstrated by its ability to
predict the dissolution rate of an individual particle in an
idealized geometry. This computational model was then
applied to ensembles of drug particles of various sizes. It will
be demonstrated that the dissolution rate becomes indepen-
dent of particle size once particle diameter decreases below a
certain threshold value. In this limit, the dissolution rate
matches the rates observed in vivo (5).
Prior to the simulation of particle dissolution, a separate
study was conducted to simulate the clearance of fully
dissolved material injected into the vitreous in three
different geometric models for the rabbit ocular anatomy.
One was the recent model advanced by Friedrich et al.(3),
the second was a model of the whole rabbit eye based upon
the geometry proposed by Park et al.(4) ,a n dt h et h i r di sa
new model proposed in this study. The three models
were approximately equal in overall size and contained
most of the same features, but differed in subtle yet
important ways that affected the rate at which material is
cleared anteriorly. The injected materials simulated were
those for which clearance data was available, represent-
ing potential drugs spanning a range in molecular
weight. The new geometric model proposed in this study
showed the best agreement in predicting the available
clearance data, and thus was selected for use in the particle
dissolution simulations.
MATERIALS AND METHODS
Software
Computational Fluid Dynamics (CFD) calculations were
conducted using FLUENT software version 6.3.26
(ANSYS, Inc., Canonsburg, PA). Geometrical models and
meshing were constructed using GAMBIT version 2.4.16
(also developed and distributed by ANSYS). Simulations
were conducted using a Dell Precision T5400 system with a
Quad processor and 4 Gigs of RAM under 32-bit Windows
XP. Because of memory limitations on this platform, some
memory-intensive simulations required being run in paral-
lel with a minimum of 2 processes.
Geometry
The geometry for the rabbit eye is shown in Fig. 1; key
dimensions appear in Tables I and II. This model contains
features that are similar to those used by others (3,4,6,7)
with the following unique distinguishing features. The
shape of the posterior segment is oval, based upon the high
resolution NMR imaging data in references (1,8). The axial
length and width of the eye and lens and the distances in
Table I were estimated from Fig. 2 of reference 1 assuming
the axial length in the figure was 1.6 cm. Separate thin shell
regionsaredefinedfortheretinaandchoroid.Thestructureof
the anterior region (ciliary body, iris, and cornea) is based
roughly on the model of Park (4), with dimensions guided by
Heys (6,7) and other information on ocular anatomy to guide
t h et h i c k n e s s e sa n dr e l a t i v ep l a c e m e n to ft h ev a r i o u st i s s u e s
(9). The lens was not included in the model except for its
shape, which was a void.
The model includes a 0.01 cm gap between the anterior
boundary of the vitreous and the ciliary body, which
effectively extends the posterior portion of the aqueous
humor nearly to the ora serrata, the anteriormost portion of
the retina. Anatomically, this has been designated as the
retrozonular space of Petit, which was not represented in
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gap has a significant physiologic impact facilitating clear-
ance of certain intravitreally injected materials as it reduces
the “bottleneck” effect restricting the efflux of materials that
are not efficiently cleared through the outer vitreous (i.e.,b y
the retina/choroid). Aqueous humor is produced on a
circumferential band on the ciliary body behind the iris
and is eliminated on a second band in front of the iris, at
the forwardmost extent of the sclera, just outside the
cornea, behind a ring of material representing the trabec-
ular meshwork. The placement of the iris was similar to
that of Heys et al.( 6,7), allowing a distance of closest
approach to the lens of 4 microns. To investigate the
potential impact of various features of ocular geometry,
similar whole-eye models were constructed for the Friedrich
and Park geometries, as shown in Fig. 2. The volumes of
the vitreous and aqueous compartments of each model are
similar, but the ratio of the length to the width is quite
different, mainly because of differences in the shape of the
vitreous and the shape and size of the lens (Table III).
Theory
Three mechanisms for drug egress from the eye, in relative
order of importance for small drug molecules such as TAC,
are as follows:
& radial outward diffusion with subsequent clearance by
the choroidal vasculature
& diffusion toward the front of the eye with clearance by
the aqueous humor turnover
& hydraulic clearance by pressure-assisted convection
through the outer sclera
Previous simulations of drug release from intravitreal
devices indicated that intraocular pressure-driven convec-
tion would have minimal impact on drug delivery for small
molecules (10,11). The convection-diffusion equation
accounts for both convection and diffusion of drug over
time:
dC
dt
þ v ! r C ¼ Dr2C ð1Þ
where C is concentration, D is the diffusion coefficient and~ v
is the velocity vector. The fluid velocity is obtained by
solving for creeping flow in a porous medium. Using
Darcy’s Law, the local volume flux rate of fluid is related to
the local pressure gradient by the equation (12):
v ! ¼ 
Kh
h
rP ð2Þ
where P is the scalar pressure variable, Kh is the
permeability of the porous medium to fluid flow and η is
the fluid viscosity. Assuming conservation of matter,
r  v ! ¼ 0 (13), we have that
r 
Kh
h
rP
  
¼ 0 ð3Þ
Table I Key Dimensions of Structures for the Rabbit Eye (Dimensions
in cm)
Axial length of eye 1.6
Width of eye at widest point 1.829
Distance, rear of eye to widest point 0.753
Distance, front of cornea to widest point 0.847
Distance, widest to flat portion of hyaloid 0.37
Distance, widest to lens rear 0.42
Distance widest to lens front 0.25
Width of lens at widest point 0.95
Thickness sclera 0.0328
Thickness choroid 0.0068
Thickness retina 0.0051
Fig. 1 Rabbit ocular geometry for the new model proposed in this study
showing the various fluid regions and key surfaces for mass flow inlet and
pressure outlet boundary conditions.
1532 Missel, Horner and MuralikrishnanEqs. 1–3 are written in general form for differential
operators, and would take on more specific forms in
selected geometries.
Material Properties, Initial Conditions, Boundary
Conditions
The aqueous humor is a simple fluid region with the
viscosity of water. All remaining regions are porous media
(porosity=1) with the hydraulic resistance values assigned in
Table IV. The band on the ciliary body behind the iris, in
direct contact with the aqueous humor, was a mass flow
inlet. The aqueous humor production rate used on this inlet
was set to 3 μL/min (2.5×10
−8kg/s for the hemisphere),
based upon the measurements of Reitsamer (14,15). This is
moderately higher than the value of 2.2 μL/min used by
Friedrich (3) and Park (4), which were apparently based
upon the earlier measurements of Kinsey (16). The band
behind the trabecular meshwork was a pressure outlet with
a zero gauge pressure. The outer sclera was maintained at a
gauge pressure of 10 Torr, representing the episcleral
venous pressure (17–19). The resistance for the vitreous was
taken from the literature (20). The last value in Table IV,
for other tissue regions (not including aqueous humor), was
taken from measurements of scleral resistance (21). The
value for the trabecular meshwork was adjusted to provide
a maximum intraocular pressure of 15 Torr. A slightly
different value was required to achieve this pressure
difference in the various geometries (see Table IV).
Two types of problems were run, requiring two separate
initial conditions. The first type was a simple bolus injection
of a diffusing material (e.g. drug) entirely in the dissolved
state. The initial condition was modeled by localizing all
drug in a 10 μL bolus in the central vitreous close to the
rear of the lens. This was modeled as a convection-diffusion
problem, in which the flow solution was obtained first,
solving only for the pressure and velocity variables in the
domain. The drug distribution was obtained by solving a
transient user-defined scalar equation in the steady-state
Fig. 2 Cross-sectional view of the ocular rabbit eye geometries for the
three different models examined. The geometry labeled “New” pertains
to the model proposed in this study.
R1 R2 X-center Z-center
Outer sclera 0.9142857 0.7525275 0 0
Choroid-sclera boundary 0.8814857 0.7197275 0 0
Retina-choroid boundary 0.8746857 0.7129275 0 0
Vitreous-retina boundary 0.8695857 0.7078275 0 0
Lens rear 0.4786011 0.4786011 0 −0.4286011
Lens front 0.5762498 0.5762498 0 −0.0437502
Cornea outside 0.8479267 0.8479267 0 0.0004540
Cornea inside 0.7898060 0.7898060 0 −0.0216670
Curved portion of hyaloid 0.3836340 0.3836340 0.5067752 0
Curved cb adjacent to hyaloid 0.3936340 0.3936340 0.5067752 0
Intersection lens equator with hyaloid 0.475 −0.37
Intersection curved & flat hyaloid 0.608141 −0.37
Intersection curved hyaloid & retina 0.834151 −0.2
Intersection outer sclera, outer cornea 0.678 −0.496548
Intersection inner sclera, inner cornea 0.650239 −0.469978
Intersection cb, tm, aqueous, sclera 0.675495 −0.445751
Table II Key Radii and
Coordinates for the Rabbit Eye
Model (Dimensions in cm)
Table III Characteristics of the Various Ocular Models
Friedrich Park New
Vitreous volume (mLs) 1.462 1.579 1.7
Aqueous volume (mLs) 0.234 0.245 0.252
Axial length (mm) 17.33 19.02 16.00
Width (mm) 8.25 8.25 9.14
Simulating Dissolution of Intravitreal Suspensions 1533fluid velocity field. This approach was used to compare the
clearance rates of diffusing materials in the various rabbit
model geometries. The time course over which the
advection was simulated was 5×10
5s for small molecules
(sucrose/fluorescein glucuronide and fluorescein) and 1.2×
10
6s for all other materials, which diffused more slowly.
The time increment was reduced until results became
independent of the timestep. This occurred for 500 s
timesteps in the case of fluorescein and sucrose and 5,000 s
timesteps for all other materials.
The second type of problem modeled the dissolution of
TAC drug crystals directly. Therefore, TAC was present in
both solid and dissolved states. These two states were
defined as separate and distinct phases in the model. At
time=0, all drug was in the solid (undissolved) phase. This
was accomplished by patch-initializing the user-defined
scalar to a constant value in the region(s) where drug exists
initially, either in a single spherical pellet or distributed
amongst suspension particles arranged geometrically in the
eye according to a particular design. Thus, the potential
impact of dissolved drug in the injected bolus (comprising
up to 96% of the volume but containing an insignificant
fraction of drug compared to that in the suspension crystals)
was ignored. The particles and vitreous gel were treated as
immiscible phases in our model; therefore, FLUENT’s
Volume of Fluid (VOF) multiphase method was used to
simulate dissolution from the surface of the drug crystal(s).
A user-defined function (UDF) was programmed to adjust
the location of the drug-gel interface based upon the flux of
drug species from the surface at a given point. The drug is
set to the solubility limit of 36 ppm at the dissolving
interface (22). At each timestep, the system measures the
amount of drug transported away from the dissolving
surface by convection and diffusion, and the UDF moves
the boundary in such a manner so as to reduce the local
volume of the drug particle by an appropriate quantity to
offset the mass of drug transported within the simulated
time increment. The rate of transport from each point on
the surface of a given particle is determined by the local
concentration gradient and by the magnitude of the fluid
velocity in that region. Hence, drug dissolution rates will
vary regionally for different particles at various locations
within the vitreous and also for different regions of an
individual particle, depending on the local environment.
The eye geometry of Fig. 1 was used for this investigation.
Particle dissolution simulations were conducted solving
all variables simultaneously: pressure, the three components
for fluid velocity, the two phases, and drug concentration
throughout the dissolved phase. The initial time increment
was extremely small (1 s), and the time increment was kept
small during the initial establishment of the quasi-steady-
state distribution of dissolved drug concentration. Once this
drug distribution was established, the time increment could
be increased to 50,000 s, which represented 0.25–1% of the
time to total suspension dissolution, providing adequate
discretization of the dissolution process. It was verified that
the simulated particle dissolution rate was not affected by
the timestep size. Simulations could be conducted to
complete particle dissolution in 50–100 CPU hours
depending upon the complexity of the suspension design.
The values of drug diffusivity in the vitreous used for
various materials appear in Table V. The value for TAC
and sucrose (or fluorescein glucuronide) was the same as the
value typically used by Maurice and co-workers for
fluorescein, a molecule of comparable molecular weight
(see for example Kaiser and Maurice (23)). The value for
albumin was taken from Maurice (24). The values for the
Dextran polymers were the same as used in Missel (11). The
value for 67 kD was assumed to be 6×10
−11 M
2s
−1 (Araie
and Maurice (25), Maurice (26)), and the values for the
other Dextran polymers were calculated assuming the
diffusivity scales with the cube root of the molecular mass
(27). Diffusivity in the aqueous humor was set to that in
vitreous.
For the bolus injection studies, the value of diffusivity in
the sclera and cornea was the value in Table V divided by
13.33, and the value of diffusivity in the retina and choroid
was one-tenth the value in the sclera/cornea. These ratios
were identified from studies on the transport of anecortave
acetate in the vitreous and in posterior ocular tissues (28).
The ratio between the diffusivities in the vitreous and sclera
was roughly comparable to estimates of other workers, who
Table IV Hydraulic Resistance Values Assigned to Various Tissue Regions
Tissue Hydraulic Resistivity
(m
−2)
Vitreous 1.19×10
13
Trabecular Meshwork, Park eye model 2.84×10
15
Trabecular Meshwork, Friedrich rabbit model 2.51×10
15
Trabecular Meshwork, new rabbit model 6.36×10
15
Interior of undissolved drug bead 1.19×10
21
All other tissues except aqueous humor 6.67×10
17
Table V Values of Vitreous Diffusivity Used for Various Materials
Material Diffusivity
(10
−10m
2s
−1)
Triamcinolone Acetonide 6.0
Fluorescein, Fluorescein Glucoronide, Sucrose 6.0
Albumin 0.84
10.5 kD Dextran 1.1
67 kD Dextran 0.6
157 kD Dextran 0.45
1534 Missel, Horner and Muralikrishnanfound this ratio to be 1:6 for the transport of small (29) and
large (30) molecules through the sclera. A low value for
diffusivity in the peripheral tissues effectively shuts them off
from being significant routes for drug elimination. Since the
main focus of the current studies is clearance from the
vitreous, this crude one-size-fits-all estimate for diffusivity
ratios in various tissues is sufficient. Predictions of drug
concentrations in the peripheral tissues themselves would
require a more accurate treatment of diffusivity in retina,
choroid and sclera. The particular value of diffusivity in the
iris, ciliary body and trabecular meshwork, set equal to the
value in the choroid and retina in these studies, would have
little impact on the clearance from the vitreous.
The tissue diffusivities assigned for the TAC dissolution
studies were as follows. The diffusivity in vitreous, and
aqueous humor was set to 6×10
−10m
2s
−1. The value in all
other tissues was set to 4.5×10
−12 m
2s
−1 (133.3 times
lower). This strategy was slightly different from that of the
bolus injection studies in two ways. First, there was no
distinction in the diffusivity in the sclera, cornea, choroid,
iris or ciliary body. Second, the diffusivity in the retina
matched that in the vitreous in order to maximize the sink
effect at the exterior vitreous (see next paragraph). Since
the egress of drug from the system was mainly by means
other than transport through peripheral tissues, the rate of
drug elimination in either type of study was not impacted
by the particular value of diffusivity in peripheral tissues.
Boundary conditions on concentration were as follows.
The value of the user-defined scalar was set to zero on the
fluid inlet at the ciliary body. For the bolus injection
simulations, this was the only boundary condition for the
diffusant, except in the case of fluorescein, in which an
infinite sink was applied in the retina, iris, and ciliary body,
to reflect the activity of an active transport mechanism
effective in these tissues. For all other materials the
predominant means of egress for drug, apart from the
insignificant transport through peripheral tissues, was by
diffusion into the posterior chamber, admixing with
aqueous humor and elimination through the trabecular
meshwork. For the intravitreal TAC suspension simula-
tions, an infinite sink was applied in the retina only.
Three types of TAC suspension models were designed:
4 μL drug confined to a 100 μL spherical depot, 16 μL drug
confinedtoa100μLsphericaldepot,and4mgdrugdispersed
uniformly throughout the entire vitreous. Suspensions of each
of these types were comprised of equisized spherical particles
of varying particle size. Particle locations were calculated
based upon the hexagonally close-packed αLa (A3’)c r y s t a l
lattice structure (http://cst-www.nrl.navy.mil/lattice/struk/
a3p.html). The interparticle spacing was fine-tuned to be
made just large enough so as to include the specified number
of particles within the region without excluding any
additional particles, accounting for the diameter of the
particle calculated. In this manner, the suspension for a
particular number of particles would be expanded just to the
point in which all of the particles would be contained within
the volume, with some of the particles on the outside just
touching the outer boundary of the depot.
Particles were not constructed explicitly in the original
mesh. Rather, the mesh adaption facility in FLUENT was
used to refine the mesh near the particle regions from an
existing mesh of half the rabbit eye geometry. This required
that the mesh after adaption be sufficiently refined in the
region of the depot such that each particle be comprised of
at least 30 cells upon marking the particle regions. For
suspensions of smaller particles, it was necessary to further
refine the particles by either one or two adaption cycles.
For the case in which the suspension was dispersed
throughout the entire vitreous, the geometry was reduced
to a wedge representing one-twelfth of the eye. This
enabled sufficient mesh refinement of the entire vitreous
region without exceeding memory limitations. The mesh
was refined as necessary to provide an initial calculated
total particle volume that was within 1% of the target.
In the Appendix, an exact analytical mathematical
relationship is derived for the time dependence of dissolu-
tion by surface erosion of a spherical drug bead suspended
in the center of a vitreous shell surrounded by an infinite
sink (approximating the choroidal clearance). The simula-
tion method was validated by verifying that it can
accurately predict the dissolution time course for this
idealized situation. The initial condition was a 4 μL
spherical bead placed in the center of a 4 mL spherical
vitreous. No pressure or flow was involved. Vitreous drug
diffusivity and all other properties were identical to those
used for the particle dissolution simulations.
RESULTS
The orderly flow pattern in the aqueous humor is visualized by
the pathlines of flow, seeded from the fluid inlet, in Fig. 3.
Fig. 4a presents a contour plot of pressure. The entire vitreous
and aqueous humor compartments are at or very close to the
assigned intraocular pressure (15 Torr), with the pressure drop
occurring almost entirely across the sclera and cornea. Fig. 4b
presents a contour plot of fluid velocity magnitude, scaled to a
maximum velocity of 10
−8m/s to illustrate the velocity
distribution in the vitreous. Fig. 4c illustrates a contour plot
of the steady-state TAC concentration for a representative
spherical suspension depot early in the dissolution process,
after the drug concentration has achieved a quasi-steady-state,
b u tb e f o r eas i g n i f i c a n ta m o u n to fm a t e r i a lh a sd i s s o l v e d .A l s o
plotted in the figure are the particle surfaces.
To illustrate the influence of the different modes of
elimination for these two materials, Fig. 5 shows represen-
Simulating Dissolution of Intravitreal Suspensions 1535tative concentration contours for fluorescein (Fig. 5a) and
157 kD Dextran (Fig. 5b)a td i f f e r e n tt i m e sa f t e rb o l u s
injection. Fig. 6 compares the clearance rates of the various
materials as measured experimentally (26,27,31–33)t o g e t h e r
with clearance rates estimated from simulations for the three
models of Fig. 2.P l o t t e di nF i g .6 are results for the ratio of
the mean aqueous and vitreous concentrations versus the
clearance rate. The slanted line represents a prediction for
materials that are eliminated only by the anterior pathway
(see Eq. 4, discussed below). The influence of varying
intraocular pressure for the geometric model of Fig. 1 is
shown in Fig. 7, over the range of 10.1–20 Torr. These
pressures were obtained by reducing the hydraulic resistance
of the trabecular meshwork to a negligible value to achieve a
pressure barely above the episcleral venous pressure of
10 Torr, to approximately twice the setting for the
normotensive condition to achieve the higher pressure.
Validation of the multiphase dissolution model outlined
in the Theory section is shown in Fig. 8 for a spherical
particle suspended in an idealized spherical vitreous
domain. The model was capable of simulating surface
dissolution by tracking the movement of the dissolving front
through an existing mesh. The two graphical insets in
Fig. 8a illustrate the shape of the drug bead at initial time
and for a time after 50% of the drug has dissolved for the
spherically symmetric reference problem. The dissolution
versus time profile predicted by the analytical result of the
Appendix was reproduced with great accuracy. The
significance of the other mathematical dependencies com-
pared is discussed below. Curves for the time dependence
of the dissolution rate for the various models (the
magnitude of the slopes of the curves) appear in Fig. 8b.
The validated framework was then applied to the
dissolution of particle suspensions. Fig. 9 illustrates selected
particle arrangements that were simulated with the VOF
model. A quantitative measure of the status of the
dissolution process as a function of time is provided by
Fig. 10, which plots the total undissolved drug for the case
of 4 mg drug divided amongst equally sized particles of
Fig. 3 Pathlines of flow seeded from the fluid inlet to the posterior
aqueous humor. Colors indicate velocity (m/s). The velocity displayed is
clipped to a maximum value of 5E-6 m/s.
Fig. 4 a Pressure displayed on the symmetry surfaces (Torr). b Velocity,
clipped to a maximum value of 10
−8m/s to illustrate contours in the
vitreous. c Dissolved Triamcinolone Acetonide concentration (grams/ml)
after the dissolution process has achieved steady state for a suspension of
16 mg Triamcinolone Acetonide divided into 276 particles confined to a
100 microliter intravitreal bolus.
1536 Missel, Horner and Muralikrishnanvarious sizes confined to a 100 μL spherical depot. Data
points are from Kim et al.( 5). A general feature of the
release profiles for the various studies is that the dissolution
rate increases and the duration to final dissolution decreases
systematically as the material is divided into smaller
particles. This trend continues until a point is reached at
which the profile appears to become independent of
particle size, as exhibited by the convergence of the curves
in Fig. 10. A convenient way to compare the influence of
particle size on dissolution rate is shown in Fig. 11, in which
the duration (time to total disappearance of undissolved
drug) is plotted versus the area ratio, defined as the total
initial suspension particle surface area normalized to that
for the largest particles modeled. When plotting the
duration data in this manner, it was discovered that the
same very simple kinetic equation provided an excellent fit
for all of these studies: y=a+b exp(-ct). The particle size for
each configuration below which further reduces in size will
not reduce the suspension lifetime by more than 1% are
indicated on each of the plots and are as follows. For a
suspension in which 4 mg drug is dispersed throughout the
entire vitreous, the size-independent limit is obtained at a
particle diameter of 77 μm. When this same 4 mg of drug is
confined to a 100 μL spherical depot within the vitreous,
the particle diameter at which the size-independent limit is
reached increases to 167 μm. If the amount of drug within
this 100 μL spherical depot is increased from 4 mg to
16 mg, the particle diameter at which the size-independent
limit is reached increases further to 428 μm.
Fig. 12 compares the size-independent results for the 4
and 16 mg spherical depots with the experimental data of
Kim et al.( 5). The predicted profiles for the aqueous humor
concentration appear in the inset. The simulation for the
16 mg depot lasts about 8 months, similar to the
experimental data. The simulation for the 4 mg depot last
about 2 months, somewhat shorter than the nearly 3-month
duration observed in vivo in both man and rabbit in various
studies (5,34). The simulations assumed the volume of the
depot remains constant at 100 μL, and the particle
positions remain stationary, whereas Kim et al. observed
that the depots tended to condense with time (5). To
crudely simulate this effect, the simulation was halted after
10 days, at which point the remaining mass of 2.7 mg was
redistributed amongst 293 particles, each particle 260 μm
in diameter, confined to a smaller 25 μL spherical depot.
The results of this simulation were delayed 10 days and
plotted as the dashed curve in Fig. 12.
Fig. 13 compares the aqueous humor concentration versus
time profiles for suspensions comprised of 19 equal-sized
particles confined to a 100 μL spherical depot in three
different locations within the vitreous, spanning the extreme
rearward and forward locations available. The duration to
total dissolution is virtually identical for all three locations.
Fig. 6 The clearance rates of various materials injected into the rabbit
vitreous as predicted by the three ocular models compared with
experiment.
Fig. 5 Concentration profiles following central bolus injection of 10 μL
intravitreal injection of a substance of concentration 1 (arbitrary units) in
the current rabbit model. a Fluorescein, 10
5s after injection. b 157 kD
Dextran, 10
6s after injection.
Simulating Dissolution of Intravitreal Suspensions 1537The aqueous humor concentration profiles show quite
similar shapes and exhibit higher maximum concentrations
the more forward the depot is placed within the vitreous.
The fraction of drug flux exiting by the anterior route at an
early dissolution time of 5E5 seconds was calculated to be
8.7, 5.0, and 3.9% of the total drug flux out of the suspension
depot for locations A, B, and C as shown in the inset.
DISCUSSION
One key assumption that is typically made by most models
of this type is that material diffusivity of small molecules in
the vitreous is identical to that in aqueous humor. This
equivalence has been supported by recent experimental
evidence indicating that the medium in which diffusion
occurs for small molecules in the vitreous gel is the aqueous
phase (35). This approach will not hold for very large
molecules or for microparticles, as eventually the vitreous
gel will exhibit diffusive resistance and slow the diffusivity
compared to that in pure water (36). By the time the
diffusing substance increases in size such that it becomes a
particle of a few microns, the diffusivity is slow enough that
the particles are essentially locked into the vitreous gel. The
diffusivities of dissolved drug in the peripheral tissues are
quite slow, and one may be tempted to discount transport
in these outer regions. If this is done, the clearance out of
the vitreous might be estimated accurately enough, but this
approach would not allow for the prediction of diffusing
material concentration in the peripheral tissues. Predictions
of delivery to these tissues would be possible to the extent
the diffusion coefficients were available, perhaps by
independent transport measurements (37).
The velocity distribution in Fig. 4b is quite comparable to
the result of the Park model (4) for the normotensive rabbit
eye. Note that in their model, flows resulted from mass flow
conditions placed on the ciliary body (2.2 μL/min) and the
outer vitreous (0.1 μL/min for the normotensive eye, based
upon an in vivo estimate (25)o f0 . 0 9 7μL/min), with the
balance of fluid cleared through the equivalent of the
trabecular meshwork, and pressures resulted from these
imposed flows. In the current model, the only mass flow
boundary condition was for fluid production at the ciliary
body (3 μL/min), and the hydraulic resistance of the
trabecular meshwork was manipulated to produce the
desired intraocular pressure. The fluid efflux rates which
result in the current model through the outer vitreous and
outer sclera are 0.075 and 0.089 μL/min, respectively, quite
comparable with the estimate of Araie and Maurice (25).
The contours in the two plots of Fig. 5 are quite different
because of the different ways in which drug is eliminated
from the eye for these two materials. The contours
resemble those observed in the study by Araie and Maurice
(25), and those calculated previously using the Friedrich
model for the rabbit posterior segment (38). Materials
Fig. 7 Influence of intraocular pressure on the clearance rate of materials
injected into the rabbit vitreous for the current geometry. The pressures
indicated represent the maximum pressure in the eye.
Fig. 8 a Validation of the method for simulating surface erosion of a 4 mg
spherical drug particle assuming a solubility limit of 36 ppm, centered in a
4 mL spherical vitreous surrounded by an infinite sink. The inset shows the
initial particle shape and the shape after half the material has eroded,
demonstrating the orderly advancement of the dissolving front. The
numerical results are indistinguishable from the exact solution (solid curve).
The prediction for an infinitely large vitreous expanse (2) is included for
reference (dotted curve). Also shown for comparison are linear and
exponential curves extrapolated from the initial dissolution rate (dashed
curves). b Rate of mass loss for the same model.
1538 Missel, Horner and Muralikrishnanwhich are cleared efficiently by transport through the outer
vitreous (such as fluorescein) will have concentration
contours resembling those of Fig. 5a, whereas materials
that are cleared entirely by the anterior pathway (such as
Dextran) will have contours resembling those of Fig. 5b.
The slanted line in Fig. 6 was calculated using a simple
mathematical relationship derived for materials that are
only eliminated by the anterior pathway, as follows (27):
Ca
Cv
¼
kvVv
f
ð4Þ
where Ca is the mean aqueous concentration, Cv is the mean
vitreous concentration, kv is the vitreous clearance rate, and
f is the aqueous humor production rate. A vitreous volume
of 1.7 mL was assumed, from the new ocular geometry, and
a value of 3 μL/min for f. The experimental points for
hydrophilic materials not cleared by the choroid come close
to this line and demonstrate the same slope over a broad
range in elimination rate. This plot provides a sensitive way
to examine how well the simulations reproduce clearance
behavior for materials cleared only by the anterior
pathway. The point for fluorescein falls quite far away
Fig. 9 Arrangements for particle suspensions. 4 mg suspensions confined to 100 μL spherical depot: a 19 particles (738 μm); b 147 particles (373 μm);
c 515 particles (246 μm). 16 mg suspensions confined to 100 μL spherical depot: d 21 particles (1133 μm); e 159 particles (577 μm); f 588 particles
(373 μm). g 4 mg dispersed uniformly throughout the entire vitreous, 1/16th of the model shown. When replicated the entire vitreous contains 942
particles (201 μm). Sizes quoted are particle diameters.
Simulating Dissolution of Intravitreal Suspensions 1539from the curve, because of the active transport mechanisms
operational in the retina and in the anterior tissues. The
infinite sink in the simulations applied in the retina is
mainly responsible for increasing the value of kv, whereas
the infinite sinks applied in the anterior tissues of the iris
and ciliary body are what produces the low concentrations
in the aqueous humor, within experimental error. The
experimental value for fluorescein glucuronide exhibits a
clearance rate appropriate for a small molecule like sucrose,
but the aqueous humor concentration falls somewhat below
the line predicted by Eq. 4. This reduced aqueous humor
concentration may be due in part to its lipophilicity, which
might cause it to partition preferentially into the iris and
ciliary body and to be cleared slightly more rapidly than
would be accounted for strictly on the basis of aqueous
humor production and elimination.
Of the three ocular models, the new geometry presented
in Fig. 1 provides the best overall match to the data for
materials not cleared by the posterior pathway, both in
terms of the elimination rate and the average concentration
Fig. 11 Influence of particle size on the duration of intravitreal
suspensions. a 4 mg TAC confined to a 100 μL spherical depot.
b 16 mg TAC confined to a 100 μL spherical depot. c 4m gT A C
dispersed throughout the entire vitreous. Trend curves represent best fits
to a first order function (see text).
Fig. 10 Influence of the number of particles on dissolution for suspension
models comprised of 4 mg of equally sized particles confined to a 100 μL
spherical depot. Data points are from reference 5.
Fig. 12 Dissolution profiles for 4 mg and 16 mg TAC confined to a
100 μL spherical vitreous depot compared with experimental data from
reference 5. Curves represent results in the limit of infinitesimally small
particles. The dashed curve for 4 mg restarts the simulation by distributing
2.7 mg of drug in a 25 μL depot to approximate the influence of depot
condensation observed in vivo. The inset shows the mean aqueous humor
concentrations predicted.
Fig. 13 Dissolution profiles for 4 mg TAC divided amongst nineteen
equally sized (738 μm) particles confined to a 100 μL spherical vitreous
depot located in three different regions of the vitreous as shown in the
inset.
1540 Missel, Horner and Muralikrishnanratio. The simulated points fall very close to the data and to
the line calculated from Eq. 4. Next in agreement is the
completed Friedrich model, which provides a reasonable
match to the elimination rate, but which systematically
underestimates the aqueous humor concentration by at
least a factor of two. The predictions from the Park model
significantly underestimate both the clearance rate and the
concentration ratio. These results are consistent with the
“bottleneck” effect apparent from Fig. 2. In comparison
with the Friedrich geometry, the Park model deepened the
lens cavity and elongated the eye, which resulted in a
narrower band connecting the vitreous and aqueous
compartments, leading to the most serious underestimates
of clearance rates and aqueous humor concentrations. The
more anatomically accurate approach produced a wider
eye than the Friedrich geometry, which increased the area
of contact between the compartments. The area of contact
was further increased by including the gap between the
vitreous and ciliary body, which might be an important
mechanism contributing to the clearance of these materials.
All three models provide comparable and adequate
predictions for the clearance and concentration ratio for
fluorescein, which falls significantly away from the curve,
having a much more rapid clearance and lower aqueous
humor concentration.
Park et al. validated the ability for their model to predict
the concentration profile within the vitreous at a particular
point in time after central bolus injection (4), but did not
offer predictions of concentrations in the aqueous humor or
the rate of anterior clearance. The original geometry
proposed by Friedrich et al.( 3) was validated similarly but
did not contain the entire aqueous humor compartment
and thus could not be used to directly simulate the aqueous
humor concentration, though in principle it could be
calculated. Models that accurately predict the anterior
concentration and clearance rates may be useful for
estimating total ocular drug content from measurements of
drug levels in the anterior compartment alone. Note that the
aqueous humor production rate of the current model is 36%
higher than that used in the previous models, and thus the
clearance of materials which exclusively use the anterior
pathway would be accelerated by this amount. The influence
of aqueous humor production rate on ocular clearance will
become less important as the strength of the retinal sink
increases. The time to total dissolution for any suspension
model would be increased by less than 50,000 s by reducing
the aqueous humor production rate to the lower value.
The simulations in Fig. 6 assumed a normotensive
pressure of 15 Torr for each of the models. The effect of
intraocular pressure will impact the shape of the clearance
curves, as illustrated for the new geometry in Fig. 7.
Pressure does not influence clearance of small molecules.
But for large, slowly diffusing materials, the clearance is
influenced by pressure in a complicated manner. As the
diffusivity decreases, the relative contribution of convective
flow on transport increases.
Fig. 8a, which demonstrates the validity of the dissolu-
tion method for a single particle in a symmetric spherical
geometry, compares the exact solution (solid curve) to three
other curves. The curve marked “infinitely large vitreous”
plots the kinetics for dissolution of the same spherical bead
in an infinite expanse. This very well-known calculation,
derived by H. P. Hopfenberg (39) more than 30 years ago,
was cast in an elegant mathematical form which provides
an intuitive comparison to release rates from other shapes
such as slabs and cylinders. The exact solution for our
current derivation reduces to the Hopfenberg curve for a
spherical particle in the limit Rv→∞. An exponential curve
projected from the initial time decay of the Hopfenberg
solution is also plotted to illustrate the approximate
resemblance between the two solutions. The exact solution
for the finite vitreous falls much closer to a linear curve at
early times, and then begins to resemble the Hopfenberg
solution at later times. Curves for the time dependence of
the dissolution rate for the various models (the magnitude
of the slopes of the curves) appear in Fig. 8b.
The simulations reported here ignore the early changes
in the relative locations of particles immediately after
dosing. The particle positions are idealized as a perfect
hexagonal array confined to a sphere and remain fixed in
space throughout the dissolution process. Also not investi-
gated in detail is the transient state at early time, during
which the drug concentration distribution achieves a quasi-
steady-state geometric distribution. The simulations can
actually be conducted with sufficient accuracy to resolve the
finer points of the time dependence after immediate
placement. If one calculates the flux through a surface
bounding the particles, the peak flux through this surface is
established within an hour. Within about 1 day it settles
down to the quasi-steady-state value. The peak flux at
1 hour exceeds the quasi-steady-state flux by only about
25%. What was ignored that is perhaps more significant is
the fact that the solution phase of the injection would have
been saturated with dissolved drug. This would actually
have suppressed the initial rate of drug dissolution until the
initial bolus of dissolved drug would have diffused away
from the injection site. But all of these approximations are
immaterial to the main emphasis of this investigation, to
determine the influence of particle size on the dissolution of
a suspension depot in the vitreous.
A surprising and perhaps somewhat nonintuitive observa-
tion is that the dissolution versus time profiles for the various
suspension models plotted in Figs. 10 and 11 become
independent of particle size as the diameter decreases below
a certain value, which depends upon the type of depot being
simulated. This does not follow the trend expected from the
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on dissolution of suspensions of finely divided particles (40–
42). In those studies, which were designed with a view
towards oral administration, the dissolution situation involves
the rapid stirring of a suspension aliquot in a relatively large
volume of release medium, such as the USP Method Type
II. In such a method, the exposed surface area of each
particle is more or less uniformly accessible to the release
medium, which is the situation of ingested drug in the
stomach after oral administration. But the situation of an
intravitreal depot is quite different. The dissolution of
particles in the interior of the depot is shielded from
dissolution compared to those near the exterior; thus, each
particle is not uniformly accessible to the same conditions
throughout the dissolution process.
Since the particle size independent limits are so much
greater than the sizes of the particles in either product, it is
justified to use the size-independent predictions to compare
simulation results with the in vivo experimental results in
Fig. 12. Each simulation provides a fair match to the trend
illustrated by the data for the 4 and 16 mg spherical depots,
although the 4 mg simulation predicts a somewhat more
rapid dissolution rate than that observed in vivo. Kim et al.
observed (5) that after injection, the depot does not remain
stationary, but appears to settle under the influence of
gravity. Thus, it is conceivable that the interparticle spacing
does not remain constant with time, but rather that the
entire depot might be condensing after injection. Since it
would be difficult to simulate a dissolution process in which
the particle locations would be changing with time, the
more crude approach described in the Results section was
used, redistributing the mass remaining after 10 days from
the initial 100 μL depot into a smaller 25 μL spherical
depot. This second curve provides a better fit to the data at
later time, extending the suspension duration to nearly
3 months. The data suggest that further reductions in the
depot volume might be occurring with time.
The predicted profiles for the aqueous humor concentra-
tion appear in the inset of Fig. 12. The peak aqueous humor
concentration appearing in the inset of Fig. 12 for both the
4 mg and 16 mg suspensions are quite similar, about
2.3 μg/mL. The aqueous humor concentrations were not
reported from the study of Kim et al.( 5). However, the
values are quite similar to the concentrations reported in
other studies (34,43). For example, Beer et al.( 34) reported
peak aqueous humor concentrations of 2–7 μg/mL follow-
ing injection of 4 mg KENALOG®-40 in human subjects.
The high value reported by Beer et al. was for the case of a
patient that had undergone vitrectomy; thus, it is not clear
whether or not the same type of depot would have formed
upon intravitreal injection into such an eye. The lower
values measured in vivo were more in line with the current
predictions. The results of Fig. 13 indicate that the depot
location could have an important impact upon the aqueous
humor concentrations. The anterior elimination pathway
constitutes a greater fraction of the overall elimination as the
depot resides closer to the hyaloid membrane.
Simulations of both types have been conducted in an
anatomically accurate human eye model. The vitreous
volume increases from 1.7 mL for the rabbit to nearly 5 mL
for the human. The volume fraction occupied by the lens is
smaller in the human ocular anatomy, and it is placed more
anteriorly in proportion to the rabbit eye. The slanted line
in Fig. 6 predicted using Eq. 4 for the human eye model
would be parallel to the line for the rabbit eye model, but a
factor of more than three-fold higher. However, the same
material injected into the two species will be eliminated
more slowly from the human eye, since the time decay for
diffusion out of a sphere varies inversely proportional to the
square of the radius (44). Since the aqueous humor
production rate is also slightly smaller in the human eye,
2.4 μL/min (45), the net prediction is that clearance out of
the human eye should proceed at about 40% of the
clearance rate for the rabbit eye. This makes the prediction
for the aqueous/vitreous humor concentration ratio com-
parable for the same material injected in the two species.
Preliminary simulations of materials injected into the
human eye allowing only for elimination through the
anterior pathway confirm the predictions above (not
shown). Simulations of the dissolution of TAC suspension
depots also allowing for an infinite sink in the retina
predicted dissolution rates that were also quite similar to
those predicted in the rabbit eye model, with similar
independence of dissolution rate and dependence of
aqueous humor concentration on depot position.
CONCLUSIONS
A computational method was developed for simulating
dissolution and drug delivery from a suspension of spheres
placed in the vitreous. The method was capable of predicting
the time dependence of the boundary between solid and
dissolved drug for each individual particle and was validated
against an analytical solution for a single spherical particle
placed in the center of an idealized spherical eye model.
Particle depots of varying configurations were located in the
vitreous of an anatomically accurate model of the rabbit eye.
This model was separately validated by demonstrating its
superior ability to predict the clearance rates of dissolved
materials after intravitreal injection, compared to two other
models in the literature.
Since the particle diameters below which dissolution rate
ceased to increase for the various depot types are much
larger than the particle sizes for either KENALOG®-40
(14–21 μM) or TRIESENCE™ (5–6 μM), it is anticipated
1542 Missel, Horner and Muralikrishnanthat the dissolution rates for these two products would be
comparable under conditions in which they form well-
defined depots within the vitreous. The credibility of these
simulations is supported by the fact that the dissolution rate
predicted in the limit of infinitesimally small particle size
matches the rate observed in vivo (5).
These simulation studies predict that KENALOG®-40
and TRIESENCE™, when injected into a well-formed
vitreous, such that a depot is formed, should have quite
similar delivery profiles. As a note added in proof,
Robinson et al. reported nearly identical vitreous half-lives
for KENALOG®-40 and for their version of a
preservative-free Triamcinolone Acetonide formulation
(46) .T h ed r u gp a r t i c l es i z eh a db e e nr e d u c e dt oa b o u t
4 μm by micronization for the preservative-free formula-
tion (5), whereas they noted a mean particle size of
17.3 μm for the lot of KENALOG®-40 used in their study
in NZW rabbits (46). Thus, the disparity in particle size
between KENALOG®-40 and their preservative-free
product is similar to what Alcon has measured between
KENALOG®-40 and TRIESENCE
™.
For the future, the current modeling approach can be
improved to incorporate:
& More details regarding the nature, dimensions, and
species variation of the retrozonular space of Petit as
they become available.
& Multiphase fluid modeling of the injection process (47),
possibly treating the injected phase as a particle
suspension.
& Insights from the tissue biomechanics of infusion
processes in other regions of the body (48).
& The effects of vitreous gel syneresis upon aging (2) and
vitrectomy (49).
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APPENDIX
The purpose of this appendix is to calculate the dissolution
rate of a bead of initial radius R0 placed in the center of a
vitreous sphere of radius Rv, having vitreous diffusivity D,
and an infinite sink applied at the outer spherical vitreous
surface (see Fig. 14). We are not interested in the details of
the early time dependence, but will calculate the rate after
the initial distribution of drug is established within the
vitreous and ignore the loss of drug required to establish
this initial distribution. We begin by first deriving the
spatial distribution of drug in the vitreous after establishing
the quasi-steady state. The applicable equation within the
vitreous sphere is
D
r2
d
dr
r2 dC
dr
  
¼ 0 ðA   1Þ
The solution to this equation is:
Cr ðÞ¼
E
r
þ F ðA   2Þ
We apply the value boundary conditions; at the particle
surface, at radius R, the drug is fixed at the solubility limit
S; and at the outer vitreous, at radius Rv, the drug
concentration is set to zero. This enables us to derive
expressions for the coefficients E and F in Eq. A-2:
CR ðÞ ¼ S ¼
E
R
þ F ðA   3Þ
CR v ðÞ ¼ 0 ¼
E
Rv
þ F ðA   4Þ
From Eq. A-4,
F ¼ 
E
Rv
ðA   5Þ
Substituting Eq. A-5 into Eq. A-3,
S ¼
E
R
 
E
Rv
¼ E
1
R
 
1
Rv
  
Fig. 14 Diagram for the reference calculation in the Appendix, a spherical
drug bead dissolving in the center of an idealized spherical vitreous domain
bounded by an infinite sink.
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E ¼
S
1
R   1
Rv
   ðA   6Þ
Substituting Eqs. A-5 and A-6 into Eq. A-3, we obtain
an expression for the spatial distribution of drug in the
vitreous:
Cr ðÞ¼
S
1
R   1
Rv
  
1
r
 
1
Rv
  
ðA   7Þ
The flux of drug through the surface at r=R is given by:
Fluxjr¼R ¼  D
dC
dr
       
r¼R
¼þ
1
R2
DS
1
R   1
Rv
   ðA   8Þ
The rate of mass loss from the bead is obtained by
integrating this flux over the entire surface:
dM
dt
¼ 4pR2»Fluxjr¼R ¼
4pDS
1
R   1
Rv
   ðA   9Þ
Now consider a shell of thickness δR on the exterior of
the spherical bead. The mass of solid undissolved drug in
this shell is:
dM ¼  4pR2rdR ðA   10Þ
where ρ is the density of undissolved drug. From Eq. A-10
we obtain the rate of change in mass of the bead with
change in radius:
dM
dR
¼  4pR2r ðA   11Þ
Note the minus sign appears in Eqs. A-10, A-11 because
mass is lost during dissolution. Using the chain rule,
dM
dt
¼
dM
dR
dR
dt
ðA   12Þ
Rearranging Eq. A-12 a n ds u b s t i t u t i n gi nf r o m
Eqs. A-9, A-11,w eo b t a i na ne x p r e s s i o nf o rt h er a t ei n
change of R with time:
dR
dt
¼
dM
dt
=
dM
dR
¼
4pDS
1
R   1
Rv
   =  4pR2r
  
¼
 DS
R2r 1
R   1
Rv
   ¼
 DS
r R   R2
Rv
   ðA   13Þ
Rearranging this equation, we obtain an expression
which is totally separated in R and t:
dR R  
R2
Rv
  
¼
 DS
r
dt ðA   14Þ
Integrating this expression on both sides,
Z
R  
R2
Rv
  
dR ¼
 DS
r
Z
dt ðA   15Þ
which leads to
 
r
DS
R2
2
 
R3
3Rv
  
¼þ t þ K ðA   16Þ
where K is a constant of integration. At t=0, R=R0, from
which we determine the expression for K:
K ¼ 
r
DS
R0
2
2
 
R0
3
3Rv
  
ðA   17Þ
Thus, the exact expression for the dependence of the
particle radius upon time may be expressed in terms of t as
a function of R as follows:
t ¼
r
DS
R0
2
2
 
R0
3
3Rv
  
 
R2
2
 
R3
3Rv
     
ðA   18Þ
Admittedly, this is not exactly in the form that we
desired; instead of an expression of R in terms of t, we have
a function of t in terms of R. But it is an extremely well-
behaved function which was used to calculate the solid
curve depicted in Fig. 8a. An instructive result is obtained
by taking the limit of this expression as Rv→∞:
t !
LimRv!1
r
2DS
R0
2   R2   
ðA   19Þ
From this we can derive an approximate expression for
R in terms of t:
R   R0
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1  
2DS
R0
2r
t
s
ðA   20Þ
The Taylor series expansion of Eq. A-20 is
R   R0  
DS
R0r
t  
D2S2
2R0
3r2 t2 þ ::: ðA   21Þ
If we limit the Taylor series expansion in Eq. A-21 to the
first-order term, we find that the drug bead radius varies
linearly with time. This is the same dependence predicted by
Hopfenberg (35) for the case of a spherical bead dissolving in
an infinite expanse. It is noteworthy that the dissolution rate
(solid curve, Fig. 8b) falls in between constant, zero-order
release and first-order release (exponential decay). The
dissolution rate exceeds the first-order dependence until the
drug bead is nearly fully exhausted, and then the dissolution
process decreases rapidly and stops suddenly. The time at
which the dissolution is complete can be calculated by
evaluating Eq. A-18 in the limit when R(t) becomes zero:
tend ¼
r
DS
R0
2
2
 
R0
3
3Rv
  
ðA   22Þ
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